Aliskiren Reduces Morning Blood Pressure in Hypertensive Patients with Diabetic Nephropathy on Hemodialysis

REFERENCES

• Yokoyama H, Okudaira M, Otani T, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care 1997; 20(5):844–847.
   PubMed Web of Science ®Google Scholar
• Iseki K, Nakai S, Yamagata K, Tsubakihara Y; for the Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant 2011; 26:963–969.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Hoshi H, Kato N, et al. Cardio-ankle vascular index to screen cardiovascular diseases in patients with end-stage renal diseases. J Atheroscler Thromb 2008; 15(6):339–344.
   PubMed Web of Science ®Google Scholar
• Joki N, Tanaka Y, Ishikawa H, et al. Optimum second screening point for detection of coronary artery disease in hemodialysis patients without advanced coronary artery disease. Am J Nephrol 2009; 29(5):420–425.
   PubMedGoogle Scholar
• Takenaka T, Sato T, Hoshi H, et al. Height constitutes an important predictor of mortality in end-stage renal disease. Cardiol Res Pract 2010; 2011:242353.
   PubMedGoogle Scholar
• Takenaka T, Tsuchiya Y, Suzuki H. High-performance hemodiafiltration and blood pressure stability. Nephron 1997; 75(1):30–35.
   PubMed Web of Science ®Google Scholar
• Okada H, Fukui M, Tanaka M, et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis 2012; 220:155–159.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Nobe K, Okayama M, et al. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy. Clin Exp Hypertens 2012; 34(4):243–248.
   PubMed Web of Science ®Google Scholar
• Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 2011; 34(3):308–313.
   PubMed Web of Science ®Google Scholar
• Morishita Y, Watanabe M, Hanawa S, et al. Long-term effects of aliskiren on blood pressure and the renin-angiotensin-aldosterone system in hypertensive hemodialysis patients. Int J Nephrol Renovasc Dis 2012; 5:45–51.
   Google Scholar
• http://www.jpnsh.org/data/CKD-kouketsuatsu.pdf
   Google Scholar
• Takenaka T, Seto T, Okayama M, et al. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study. Am J Nephrol 2012; 35(5):416–423.
   PubMed Web of Science ®Google Scholar
• Mimura T, Takenaka T, Kanno Y, Moriwaki K, Okada H, Suzuki H. Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases. J Hum Hyerterns 2008; 22(1):38–47.
   PubMed Web of Science ®Google Scholar
• Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2006; 1:730–737.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Mimura T, Kanno Y, Suzuki H. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Am J Nephrol 2005; 25:417–424.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Ohno Y, Takenaka T, et al. Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes. Clin Exp Hypertens 2011; 33(2):100–105.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy. Clin Exp Hypertens 2005; 27(2–3):129–138.
   PubMed Web of Science ®Google Scholar
• http://docs.jsdt.or.jp/overview/pdf2012/p03.pdf
   Google Scholar
• Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340(17):1321–1328.
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 2001; 280(3):F480–F486.
   PubMed Web of Science ®Google Scholar
• Sander D, Klingelhöfer J. Diurnal systolic blood pressure variability is the strongest predictor of early carotid atherosclerosis. Neurology 1996; 47:500–507.
   PubMed Web of Science ®Google Scholar
• Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int 2008; 73(6):679–683.
   PubMed Web of Science ®Google Scholar
• Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized double-blind study. J Hum Hypertens 2010; 24:93–103.
   PubMed Web of Science ®Google Scholar
• Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther 1999; 66(4):367–373.
   PubMed Web of Science ®Google Scholar
• http://www.theheart.org/article/1331173.do
   Google Scholar
• Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84(2):489–539.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Saruta T, Brosnihan KB, Ferrario CM. Angiotensin II-induced drinking in water-deprived and nephrectomized dogs. Jpn Heart J 1987; 28:211–219.
   PubMedGoogle Scholar
• Beasley D, Brenner BM. Role of nitric oxide in hemodialysis hypotension. Kidney Int 1992; 38 (Suppl):S96–S100.
   Google Scholar
• Takenaka T, Kojima E, Sueyoshi K, et al. Seasonal variations of daily changes in blood pressure among hypertensive patients with end-stage renal diseases. Clin Exp Hypertens 2010; 32(4):227–233.
   PubMed Web of Science ®Google Scholar